TuHURA Biosciences Inc. Ordinary Shares HURA 深 滬
等待開盤 08-30 09:30:00 美东时间
2.70
-0.110
-3.91%
華盛通- 最 高2.82
- 今 開2.81
- 成交量 22.05万股
- 最 低 2.69
- 昨 收 2.81
- 總市值 1.18亿
- 52周最高 7.93
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.80
- 委 比 54.91%
- 總股本 4368.04万
- 歷史最高 190225.00
- 量 比 0.75
- 振 幅 4.63%
- 歷史最低 1.80
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TuHURA Biosciences Q2 EPS $(0.21) Misses $(0.14) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.14) by 53.28 percent. This is a 51.16 percent increase over losses of $(0.43) per share
08-15 04:42
美股牛股 | 特朗普重新分类大麻危险等级消息引爆市场，Tilray飙升超过41%
特朗普重新分类大麻危险等级消息引爆市场，Tilray飙升超过41%；Q2业绩超市场预期，Telos Corporation隔夜飙升超60%>>
08-12 14:45
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
08-12 01:06
TuHURA Biosciences announces inclusion in Russell 3000 and Russell 2000 indexes
TuHURA Biosciences (NASDAQ:HURA) on Tuesday said it has been added to the Russell 3000 Index, with automatic inclusion in the Russell 2000 Index, as a part of the 2025 Russell indexes annual reconstit...
07-01 21:24
TuHURA Biosciences Completes Acquisition of Kineta
Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involvi...
06-30 20:50
Kineta Approves Merger with TuHURA Biosciences
The latest announcement is out from Kineta ( ($KANT) ). On June 23, 2025, Kinet...
06-25 04:40
TuHURA Biosciences and Kineta stockholders approve proposed deal
TuHURA Biosciences (NASDAQ:HURA) said that its stockholders have approved the proposed merger with Kineta during their special meeting. In addition to the merger approval, TuHURA Biosciences announced...
06-24 05:19
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to ...
06-24 05:00
TuHURA Biosciences Approves Executive Salary Increases
TuHURA Biosciences ( ($HURA) ) has shared an update. On June 6, 2025, TuHURA Bi...
06-12 19:27
FDA Removes Manufacturing-Related Partial Clinical Hold On TuHURA's Phase 3 Accelerated Approval Trial For IFx-2.0, Allowing Trial To Proceed As Agreed To Under Previously Announced SPA Agreement With FDA
Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma
06-09 20:11
